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Abstract 
HIV-1-associated neurocognitive disorders (HAND) continue to be a major concern 
in the infected population, despite the widespread use of combined antiretroviral therapy 
(cART). Growing evidence suggests that an imbalance between matrix 
metalloproteinases (MMPs) and endogenous tissue inhibitors of MMPs (TIMPs) 
contributes to the pathogenesis of HAND. In our present study, we examined protein 
levels and enzymatic activities of MMPs and TIMPs in both plasma and cerebrospinal 
fluid (CSF) samples from HIV-1 patients with or without HAND and HIV-1-negative 
controls. Imbalances between MMPs and TIMPs with distinct patterns were revealed in 
both the peripheral blood and CSF of HIV-1 patients, especially those with HAND. In the 
peripheral blood, the protein levels of MMP-2, MMP-9, TIMP-1, TIMP-2, and the 
enzymatic activities of MMP-2 and MMP-9 were increased in HIV-1 patients with or 
without HAND when compared with HIV-1-negative controls. The enzymatic activity of 
MMP-2, but not MMP-9, was further increased in plasma samples of HAND patients 
than that of HIV-1 patients without HAND. Notably, the ratio of MMP-2/TIMP-2 in 
plasma was significantly increased in HAND patients, not in patients without HAND. In 
the CSF, MMP-2 activity was increased, but the ratio of MMP-2/TIMP-2 was not altered. 
De novo induction and activation of MMP-9 in the CSF of HAND patients was 
particularly prominent. The imbalances between MMPs and TIMPs in the blood and 
CSF were related to the altered profiles of inflammatory cytokines/chemokines and 
monocyte activation in these individuals. In addition, plasma from HIV-1 patients directly 
induced integrity disruption of an in vitro blood-brain barrier (BBB) model, leading to 
increased BBB permeability and robust transmigration of monocytes/macrophages. 
  
These results indicate that imbalances between MMPs and TIMPs are involved in BBB 
disruption and are implicated in the pathogenesis of neurological disorders such as 
HAND in HIV-1 patients.   
  
Introduction  
The HIV-1 pandemic has claimed over 20 million lives, with approximately 37 
million people worldwide living with HIV-1/AIDS (http://aidsinfo.unaids.org/), and will 
continue to contribute to human morbidity and mortality as there is no vaccine or 
curative treatment available. HIV-1 is neurovirulent, causing neurological diseases such 
as HIV-1-associated neurocognitive disorders (HAND) in roughly 20% of infected 
individuals and 60% of patients in the advanced stages of HIV-1 infection (Clifford, 2008; 
Lindl et al., 2010; Valcour et al., 2011). The incidence of a  subclinical neurological 
phenotype is much higher. Autopsy studies of patients with AIDS, the most severe 
phase of HIV-1 infection, have revealed that pathologic abnormalities of the central 
nervous system (CNS) occur in 75 - 90% of cases examined (Kay et al., 1991; Trujillo et 
al., 2005). The widespread use of combined antiretroviral therapy (cART) has 
dramatically decreased the incidence of severe neurological diseases. However, milder 
forms of HIV-1-associated neurological disorders have become more prevalent as 
patients live longer due to the use of cART (Joska et al., 2011; Woods et al., 2009). For 
example, cART has profoundly changed the clinical phenotypes of HAND that is 
classified into three categories including (1) asymptomatic neurocognitive impairment 
(ANI), (2) mild neurocognitive disorder (MND), and (3) HIV-1-associated dementia 
(HAD). While the incidence of HAD, the most severe form of HAND, has significantly 
declined in the cART era, the incidence of the milder forms of HAND, such as ANI and 
MND, persists or even increases (Tan and McArthur, 2012). Pathological studies have 
indicated that neuroinflammation and neural cell death occur in HAND patients, possibly 
due to increased transmigration of infected and/or activated monocytes/macrophages 
  
across the blood-brain barrier (BBB) into the brain (Lakhan et al., 2013; Louboutin et al., 
2010; Louboutin et al., 2011; Louboutin and Strayer, 2012; Power et al., 1993; 
Rosenberg et al., 1998; Spindler and Hsu, 2012; Strazza et al., 2011; Webster and 
Crowe, 2006). However, the pathogenesis of this progression remains largely unclear 
(Shawahna, 2015).  
The BBB is a dynamic interface between the peripheral circulation and the CNS, 
which controls the influx and efflux of biological substances needed for brain metabolic 
processes as well as neuronal functions. Thus, the structural and functional integrity of 
the BBB is vital in maintaining brain homeostasis (Bernacki et al., 2008). The BBB is 
composed of specialized brain microvascular endothelial cells (BMECs) that are 
surrounded by astrocytes and pericytes to cooperatively form and maintain the cerebral 
microvasculature (Itoh et al., 2011). It has been reported that the BBB capillaries are 50-
100 times tighter than peripheral microvessels as a result of complex tight junctions 
(TJs) between adjacent cells (Abbott, 2002; Aijaz et al., 2006; Redzic, 2011). TJs are 
multiprotein complexes that mediate cell-cell adhesion and regulate transportation 
through the extracellular matrix (ECM). The BBB cells and TJs proteins are linked to the 
ECM that forms a milieu, thereby playing a prominent role in maintaining the integrity of 
the BBB and in providing signaling to neural cells. Therefore, BMECs together with the 
closely associated astrocytes, pericytes, neurons, TJs, and the ECM constitute a 
“neurovascular unit” that is essential for the health and function of the CNS (del Zoppo, 
2009). It has been shown that the over expression and activation of matrix 
metalloproteinases (MMPs) can injure the BBB, in part, by digesting the TJs and ECM 
of the BBB (Louboutin, 2010). 
  
In humans, there are 23 related, but distinct, MMPs including 17 soluble MMPs 
and 6 membrane-type MMPs (MT1-MMP to MT6-MMP) (Klein and Bischoff, 2011; 
Nagase et al., 2006; Nagase and Woessner, 1999; Nelson and Bissell, 2006; Ra and 
Parks, 2007; Seiki, 2003; Vincenti, 2001). All MMPs are initially synthesized as 
enzymatically inactive forms (proMMPs or zymogens), which are subsequently 
processed to generate the active forms (Klein and Bischoff, 2011; Nagase et al., 2006; 
Nagase and Woessner, 1999; Nelson and Bissell, 2006; Ra and Parks, 2007; Seiki, 
2003; Vincenti, 2001). Collectively, these active MMPs are capable of degrading all 
types of ECM proteins that form the connective materials between cells and around 
tissues, thereby playing a key role in tissue remodeling and many other important 
processes. MMP proteolysis is tightly regulated at multiple levels including inhibition by 
endogenous tissue inhibitors of MMPs (TIMPs) (Cao et al., 1996; Gomez et al., 1997; 
Klein and Bischoff, 2011), activation of proMMPs (Galis and Khatri, 2002; Ra and Parks, 
2007), and induction of gene expression (Klein and Bischoff, 2011; Nagase and 
Woessner, 1999; Vincenti, 2001). Excessive expression and activation of MMPs have 
been linked to many diseases such as rheumatoid arthritis, cancer metastasis, and 
neurological disorders (Cheng et al., 2000; Klein and Bischoff, 2011; Kontogiorgis et al., 
2005; Lakhan et al., 2013; Mun-Bryce and Rosenberg, 1998; Rosenberg et al., 1998; 
Strazza et al., 2011). Growing evidence suggests that an imbalance between MMPs 
and TIMPs contributes to HAND by disrupting the BBB to allow the penetration of 
infected cells and neurotoxic substances (Lakhan et al., 2013; Louboutin et al., 2010; 
Louboutin et al., 2011; Louboutin and Strayer, 2012; Power et al., 1993; Rosenberg et 
al., 1998; Spindler and Hsu, 2012; Strazza et al., 2011; Webster and Crowe, 2006) and 
  
degrading nerve tissue proteins to induce death of neurons (Webster and Crowe, 2006). 
In the present study, we examined protein levels and enzymatic activities of MMPs and 
TIMPs in both plasma and cerebrospinal fluid (CSF) samples from HIV-1 patients with 
or without HAND and HIV-1-negative controls (HD). We also profiled inflammatory 
cytokines/chemokines and monocyte/macrophage activation in these clinical samples. 
We found that imbalances between MMPs and TIMPs with distinct patterns occurred in 
both the blood and CNS in HIV-1 patients, especially those with neurocognitive 
disorders. The increased ratio of MMP-2/TIMP-2 in the peripheral blood and de novo 
induction and activation of MMP-9 in the CSF were especially significant in HAND 
patients, suggesting that imbalances between MMPs and TIMPs may contribute to BBB 
disruption and dysfunction in HAND patients. 
 
Materials and Methods  
Study subjects and ethics statement 
Frozen plasma samples from 9 HIV-1 patients who had no neurocognitive 
disorders (NN) and 19 HAND patients were kindly provided by the National NeuroAIDS 
Tissue Consortium (NNTC, Rockville, MD) through four collection units including the 
Texas Repository for AIDS Research (Dr. Gelman BB.), the Manhattan HIV Brain Bank 
at the Mount Sinai Medical Center (Dr. Morgello S.), the UCLA National Neurological 
AIDS Bank (Drs. Lucey G., Im K., and Wei B.), and the California NeuroAIDS Tissue 
Network (CNTN) at UCSD (Dr. Ellis RJ.). The NNTC, funded by NIMH and NINDS, has 
collected, banked, and distributed samples of central and peripheral nervous system 
tissues, cerebrospinal fluid (CSF), blood, and other organs from HIV-1-positive and -
  
negative individuals to support researchers worldwide to study pathogenesis of 
NeuroAIDS disorders. All samples were banked by NNTC according to strictly 
established protocols to ensure uniformity across the four clinical sites. Upon study 
entry, participants underwent a comprehensive psychometric evaluation to determine 
past and current substance use disorders, psychiatric illness, and neuropsychological 
(NP) functioning, as previously described (Clifford and Ances, 2013). Neurological 
examinations were also performed along with immunological (CD4 T cell count) and 
virological (plasma and CSF HIV-1 viral load) testing (Morgello et al., 2001). The NNTC 
uses an in vivo neurocognitive clinical diagnosis that is based on subjects’ pre-mortem 
neurological and/or NP evaluation or by post-mortem review of records (if the subject 
could not be examined). The definitions are as follows: 1) Neurocognitively Normal (NN): 
Subjects had no significant cognitive complaints, no evidence of impairment on NP 
testing, and/or no loss of functional capacity; 2) ANI: Subjects had no significant 
cognitive complaints, but NP testing revealed evidence of mild NP abnormalities that do 
not impair activities associated with daily living or manifest themselves with clinical 
symptoms; 3) MND: Subjects or others reported symptoms of cognitive decline, 
evidence of mild NP impairment, decline in functional capacity that does not reach 
severity required to diagnose. Subjects may or may not have had a diagnostic 
evaluation to rule out other causes of cognitive impairment; and 4) HAD: Subjects or 
others reported symptoms of cognitive decline, evidence of moderate or severe NP 
impairment on NP testing, decline in functional capacity that reaches the level of 
dementia. Subjects may or may not have had a diagnostic evaluation to rule out other 
causes of NP impairment. The demographics and clinical characteristics of these NN 
  
and HAND patients are summarized in Table 1 and Table S1. Peripheral blood from 9 
HIV-1-negative (HD) individuals who were matched for the gender, age, and ethnicity of 
HAND patients was collected in BD vacutainer tubes (BD Biosciences, Franklin Lakes, 
NJ). Blood samples were separated into plasma and peripheral blood mononuclear cells 
(PBMCs) that were stored at -80°C until use. 
Frozen CSF samples from 8 HIV-1 patients who were diagnosed with HAND were 
kindly provided by the California NeuroAIDS Tissue Network (CNTN) at UCSD (Dr. Ellis 
RJ.) through the NNTC (Rockville, MD) (Table 2). Nine CSF samples from HD 
individuals who had CNS symptoms due to unidentified pathogens were obtained from 
the Lee Biosolutions (Maryland Heights, MO) or Indiana University Medical Center 
(Table 2).  
Peripheral blood and CSF samples from HD individuals were obtained under an 
IRB protocol approved by the Indiana University School of Medicine Institutional Review 
Board. Written informed consent was obtained from each participant before specimen 
collection. 
 
Cell lines and cell culture 
Human glioblastoma cell line U87MG (kindly provided by Dr. Ivan M., IUSM, 
Indianapolis, IN) was cultured in high glucose Dulbecco’s modified eagle’s medium (H-
DMEM, GE Healthcare Life Sciences, Logan, UT) supplemented with 10% fetal bovine 
serum (FBS) (Atlanta Biologicals, Flowery Branch, GA), 100 U/mL penicillin, and 100 
U/mL streptomycin (GE Healthcare Life Sciences). Human capillary microvascular 
endothelial cell line hCMEC/D3 (Cellutions Biosystem, Birlington, Ontario, Canada) was 
  
cultured in EndoGRO-2MV Complete Culture Media (EMD Millipore, Billerica, MA) 
supplemented with human basic fibroblast growth factor (bFGF, Sigma-Aldrich, St. 
Louis, MO), 100 U/mL penicillin, and 100 U/mL streptomycin according to the 
manufacturer’s protocol. U87MG and hCMEC/D3 cells were cultured at 37°C in a 5% 
CO2 incubator, and the medium was changed every 2-3 days. 
 
Gelatin zymography assay 
Gelatinase activity of human plasma and CSF were determined by a sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gelatin zymography 
assay as previously described (Toth et al., 2012). Briefly, plasma or CSF was mixed 
with sample buffer in the absence of any protein-reducing agents and loaded onto 
polyacrylamide gels containing 0.1% (w/v) gelatin for electrophoresis (Novex 10% 
Zymogram Gelatin Protein Gels, Invitrogen, Carlsbad, CA). After electrophoresis, gels 
were washed in renaturing buffer, followed by washing in developing buffer, and 
subsequently incubated in developing buffer at 37°C for 40 h. Thereafter, gels were 
stained with a Colloidal Blue Staining Kit (Invitrogen, Carlsbad, CA), and gelatinolytic 
activity was detected as clear bands on the blue background. The activity of MMPs was 
determined by densitometric scanning of the bands using an EC3 Imaging System 
(UVP, Upland, CA). Photographic densities were analyzed using NIH Image J software 
(National Institutes of Health, Bethesda, MD) to determine the enzymatic activity of 
MMP-2 (62-72 kDa) and MMP-9 (82-92 kDa). 
 
Enzyme-linked immunosorbent assay (ELISA) 
  
Total protein concentrations of MMP-2, MMP-9, TIMP-1, TIMP-2, soluble CD14 
(sCD14), and soluble CD163 (sCD163) in plasma and CSF samples were determined 
using ELISAs. All the ELISA kits were purchased from R&D Systems (Minneapolis, MN). 
ELISA results were documented using a microplate reader system (BioTek, Winooski, 
VT). 
 
Multiplex immunoassays 
CSF concentrations of 38 human cytokines/chemokines (sCD40L, EGF, Eotaxin, 
FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-
1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-
17A, IP-10, MCP-1, MCP-3, MDC, MIP-1α, MIP-1β, TGF-α, TNF-α, TNF-β, and 
VEGF) were simultaneously measured using a magnetic bead-based multiplex kit 
(HCYTMAG-60K-PX38, EMD Millipore, Billerica, MA) as per the manufacturer’s 
instruction. Samples were incubated with beads at 4°C for 16 h with shaking at 500 rpm, 
and subsequently washed twice using a hand-held magnet plate washer (eBioscience, 
San Diego, CA). The beads were incubated with the biotinylated detection antibody for 
1 h at room temperature with shaking at 500 rpm, followed by incubation with 
streptavidin-PE for 30 min at room temperature with shaking at 500 rpm. After washing 
twice, the beads were resuspended in shield buffer and read on a Luminex-100 system 
(EMD Millipore, Billerica, MA) with a setting of 40 beads per bead set and 150 sec per 
well. The standards (3.2 to 10,000 pg/mL) provided in the HCYTMAG-60K-PX38 kit 
were run on each plate in duplicate, and used to calculate the concentrations of 
cytokines/chemokines using the Bio-Plex Manager Software (Bio-Rad, Hercules, CA). 
  
In vitro BBB model for analysis of BBB permeability and cell transmigration 
An in vitro BBB model consisting of hCMEC/D3 and U87MG cells in co-culture on 
opposite sides of a collagen-coated, 0.4 µm pore-size tissue culture insert (for 
permeability assay) or 3.0 µm pore-size tissue culture insert (for cell transmigration 
assay) (Corning, Tewksbury, MA) was established as previously described (Eugenin 
and Berman, 2003; Eugenin et al., 2011). Briefly, U87MG cells were seeded on the 
Poly-L-Lysine coated basolateral side of the transwell insert at a density of 2×104, and 
hCMVEC/D3 cells were seeded on the apical side of the insert (2×104/insert) with type I 
collagen coating. Co-cultures were maintained for 48-72 h to enable contact between 
astrocyte endfeet with hCMVEC/D3 cells on the opposite side of the model as 
previously described (Eugenin et al., 2011). 
To analyze the effects of plasma from HIV-1 patients on BBB permeability, 25% 
(v/v) plasma (in EGM-2MV medium) from healthy donors or HIV-1 patients was added 
to hCMEC/D3 cells in the transwell inserts and incubated for 24 h at 37°C in a 5% CO2 
incubator. After washing twice with 1x HBSS to remove the medium, FITC-dextran in 1x 
HBSS at 1 mg/mL was added to the inserts, while 1x HBSS was added to the lower 
chamber. The HBSS from the basolateral lower chamber was sampled after treatment 
for 1 h to assess the degree of FITC-dextran flux across the BBB. Fluorescence 
intensity of FITC-dextran was measured at excitation wavelength 488 nm and at 
emission wavelength 525 nm using a Synergy 4 microplate reader (Biotek, VT). The 
degree of diffused FITC-dextran was expressed as fold changes in fluorescence 
intensity relative to media from vehicle controls (Alabanza and Bynoe, 2012). 
To analyze the effects of plasma from HIV-1 patients on cell transmigration across 
  
the BBB model, 25% (v/v) plasma (in EGM-2MV medium) from healthy donors or HIV-1 
patients was added to hCMEC/D3 cells in the transwell inserts and incubated for 24 h at 
37°C in a 5% CO2 incubator. After washing away the plasma, fresh PBMCs (1×106) 
from healthy donors were gently added to the top chambers of hCMEC/D3 layers 
growing on the insert filters. Cells were incubated at 37°C for 4 h to allow cell 
transmigration to the bottom chambers. The entire population of transmigrated cells 
present in each bottom chamber was collected by centrifugation at 300 x g for 10 min. 
The bottom sides of the insert filters were also rinsed with 2% FBS/2 mM EDTA to 
detach any adherent cells as previously described (Bahbouhi et al., 2009). MCP-1 (R&D 
Systems, Minneapolis, MN) at 100 ng/mL was used in every cell transmigration 
experiment as a positive control, as MCP-1 has been widely used for analyzing cell 
transmigration across the BBB (Eugenin et al., 2006). 
 
Flow cytometric analysis 
PBMCs and transmigrated cells were subjected cell surface staining with 
fluorochrome-conjugated antibodies against CD45 (a marker of human hematopoietic 
cells or leukocytes) and CD14 (a marker of human monocytes/macrophages) and flow 
cytometric analysis to determine cell numbers and types. Isotype-matched control 
antibodies were used as negative controls in each staining. All specific and control 
antibodies were purchased from BD Biosciences (Franklin Lakes, NJ). Cells were 
subjected to surface staining with antibodies in the dark at 4°C for 30 min. After washing 
3 times with 2% FBS/PBS, cells were fixed with 2% paraformaldehyde (PFA) and 
subjected to flow cytometric analysis using a BD Accuri C6 flow cytometer to determine 
  
cell numbers and types. Flow cytometric analysis data were analyzed using FlowJo 
software (Tree Star, San Carlos, CA). 
 
Proteomic analysis of CSF samples 
Proteomic analysis of CSF samples was conducted in the Purdue Proteomics 
Facility, Purdue University (West Lafayette, IN). Briefly, each sample was denatured by 
cold acetone, reduced, alkylated, and followed by digestion with a Lys-C/trypsin mixture. 
Samples were cleaned using a silica-based C18 MacroSpin Column (Supelco, 
Bellefonte, PA). The final peptide concentration was determined using a BCA assay 
(Pierce, Rockford, IL). The samples were run on a nanoEksigent 425 HPLC system 
coupled to the Triple TOF 5600 plus (Sciex, Framingham, MA), and analyzed for 120 
min at 300 nL/min over the cHiPLC nanoflex system. The trap column was a Nano 
cHiPLC 200 µm x 0.5 mm ChromXP C18-CL 3 µm 120 Å followed by the analytical 
column, the Nano cHiPLC 75 µm x 15 cm ChromXP C18-CL 5 µm 120 Å. Each sample 
was injected into the Triple TOF 5600 plus through the Nanospray III source equipped 
with emission tip from New Objective. Peptides from the digestion were eluted from the 
columns using a mobile phase A of purified H2O/0.1% formic acid (FA) and a mobile 
phase B of ACN/0.1% FA.  With a flow rate of 0.3 µL/min, the method started at 95% A 
for 1 min followed by a gradient of 5% B to 35% B in 90 min and from 35% B to 80% B 
in 2 min. 80% B was held for 5 min before being brought to 5% B and held for 20 min. 
The data acquisition was performed to monitor 50 precursor ions at 250 ms/scan. 
Mascot Daemon v.2.4.0 (Matrix Science, Boston, MA) was used for database searches 
against the UniProt_human database. 
  
Statistical analysis 
Statistical analysis was performed using SPSS software 24.0 and GraphPad Prism 
6.0 (La Jolla, CA). Data were expressed as mean ± standard error of the mean (SEM) 
or mean ± standard deviation (SD) unless otherwise indicated. All data were tested for 
suitability for parametric or non-parametric analysis in SPSS. For comparing the 
biological factors assessed in this study between the two groups of HD and HAND CSF 
samples, independent t-test or Mann-Whitney U-test was used, as appropriate. For 
comparison of more than two groups, one-way ANOVA analysis or Kruskal-Wallis test 
was performed, as appropriate. Dichotomous variables such as gender and ethnicity 
were compared using Chi-squared test. Correlations were calculated using Spearman’s 
correlation coefficient analysis. Logistic regression analysis or multiple linear regression 
analysis was performed for taking into account the effect of covariates of age, sex and 
race. The p values shown in each figure are adjusted p values. A p value of <0.05 was 
considered statistically significant. Each in vitro experiment was performed at least 3 
times with cells prepared from independent cell cultures.  
 
Results 
An imbalance between MMPs and TIMPs was revealed in the peripheral blood of 
HAND patients 
Excessive expression and activation of MMPs are associated with BBB breakdown 
in many human diseases including HIV-1 infection (Baker, 2002; G.A. Rosenberg, 1998; 
Louboutin et al., 2010; Louboutin et al., 2011; Louboutin and Strayer, 2012; Power, 
1993; Spindler and Hsu, 2012; Strazza et al., 2011; Webster and Crowe, 2006). To 
  
confirm the increased expression of MMPs in HIV-1 patients and explore whether these 
MMP alterations were more dramatic in HIV-1 patients with HAND, we determined the 
protein levels of MMP-2 and MMP-9, two of the most important members of the MMP 
family, in plasma samples from 9 HD, 9 NN, and 19 HAND individuals. The 
demographics and clinical characteristics of these study subjects are summarized in 
Table 1 and Table S1. As shown in Fig. 1A, MMP-2 and MMP-9 were present in all 
plasma samples analyzed. Compared to HD, both NN and HAND had significantly 
higher protein levels of MMP-2 (p < 0.01 and p < 0.001) and MMP-9 (p < 0.01) (Fig. 1A). 
However, there were no significant differences between NN and HAND in their plasma 
levels of either MMP-2 or MMP-9 (Fig. 1A). 
We also quantified the protein levels of TIMP-1 and TIMP-2 in the plasma samples 
of HD, NN, and HAND individuals, as these two tissue inhibitors of MMPs are mainly 
involved in the regulation of MMP-9 and MMP-2 activities, respectively (Gomez, 1997; 
Klein and Bischoff, 2011). We found that both TIMP-1 and TIMP-2 were detectable in 
plasma samples from all subjects studied (Fig. 1B), indicating that they are constitutively 
present in the peripheral blood. Compared to HD, both NN and HAND had significantly 
higher protein levels of TIMP-1 (p < 0.001) and TIMP-2 (p < 0.01 and p < 0.001) (Fig. 
1B). There were no significant differences between NN and HAND in their plasma levels 
of either TIMP-1 or TIMP-2 (Fig. 1B). Interestingly, when we further analyzed the ratio of 
MMP-2/TIMP-2 or MMP-9/TIMP-1, we found that HAND had a significantly higher ratio 
of MMP-2/TIMP-2 when compared with HD (p < 0.05), whereas NN had a similar ratio of 
MMP-2/TIMP-2 with that in HD (Fig. 1C). There were no differences in the MMP-
9/TIMP-1 ratio among HD, NN, and HAND (Fig. 1C).  
  
Enzymatic activity of MMP-2 and MMP-9 were increased in the peripheral blood of 
HAND patients 
All MMPs are initially synthesized as enzymatically inactive forms (proMMPs or 
zymogens), which are subsequently processed to generate the active forms (Klein and 
Bischoff, 2011; Nagase et al., 2006; Nagase and Woessner, 1999; Nelson and Bissell, 
2006; Ra and Parks, 2007; Seiki, 2003; Vincenti, 2001). Since we found that the plasma 
levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 were dysregulated in HIV-1 patients, we 
next used the gelatin zymography assay to analyze the enzymatic activity of plasma 
MMP-2 and MMP-9. The enzymatic activities of both MMP-2 and MMP-9 in NN and 
HAND samples were significantly higher than those in HD samples (Fig. 2A, 2B). 
Notably, MMP-2 activity was even higher in HAND patients when compared with NN 
individuals (p < 0.05), while MMP-9 activity in NN and HAND samples was not different 
(Fig. 2B). 
 
Elevated plasma levels of MMP-2 and TIMP-2 positively correlated with markers of 
viral pathogenesis  
To determine whether the elevated plasma levels of MMPs and TIMPs were 
associated with markers of viral pathogenesis, we analyzed the correlations among 
HIV-1 viral load, CD4 T cell count, and plasma levels of MMPs and TIMPs. We found 
that the plasma level of MMP-2 positively correlated with viral load (Fig. 3A, r = 0.66, p = 
0.0001) and negatively correlated with CD4 T cell count (Fig. 3B, r = - 0.40, p = 0.03). 
Plasma levels of TIMP-2 positively correlated with viral load (Fig. 3C, r = 0.52, p = 
0.005), and negatively correlated with CD4 count (Fig. 3D, r = - 0.46, p = 0.01). No 
  
correlations were found between plasma level of MMP-9 and either viral load or CD4 T 
cell count (data not shown). 
 
Plasma from HIV-1 patients disrupted the BBB integrity and increased monocyte 
transmigration across an in vitro BBB model 
Since we demonstrated that MMP-2 and MMP-9 levels and proteolytic activities 
were elevated in plasma samples from HIV-1 patients, we tested whether plasma from 
HIV-1 patients was able to directly affect BBB integrity. As shown in Fig. 4A, plasma 
from HIV-1 patients increased the BBB model permeability by 2-fold when compared 
with plasma from HD individuals (p = 0.05). The increased BBB permeability was 
partially mediated by excessive expression and activation of MMPs in the plasma, as 
pre-treatment of the BBB with GM6001, a pan-MMP inhibitor, ameliorated the 
impairment of the BBB permeability (data not shown). To examine whether the impaired 
BBB integrity induced by plasma from HIV-1 patients could further lead to an increased 
penetration of leukocytes (CD45+ cells), especially monocytes/macrophages, we carried 
out a cell transmigration assay by adding PBMCs from HD individuals into upper 
chambers of the in vitro BBB model treated with plasma from HD or HIV-1 subjects. 
Compared to HD plasma treatment, treatment with plasma from HIV-1 patients 
significantly increased the numbers of transmigrated leukocytes in the lower chambers 
(Fig. 4B, 4C). Flow cytometric analysis revealed that the majority of transmigrated 
leukocytes were CD45+CD14+ monocytes/macrophages (Fig. 4B, 4C). As MCP-1 is a 
potent monocyte/macrophage attractant and plays a critical role in promoting migration 
of monocytes/macrophages across the BBB of HIV-1 patients, we also tested whether 
  
addition of MCP-1 in lower chambers increased transmigration of 
monocytes/macrophages. We found that MCP-1 significantly increased transmigration 
of monocytes/macrophages (Fig. 4C). Our findings indicate that plasma from HIV-1 
patients directly impairs the BBB integrity and function, leading to an enhanced 
transmigration of monocytes/macrophages into the CNS. 
 
MMPs and TIMPs were dysregulated in the CSF of HAND patients 
The increased protein levels and enzymatic activity of MMPs in the peripheral 
blood of HIV-1 patients are likely involved in over-degradation of ECM components of 
the BBB, thereby disrupting BBB permeability and function. Damaged BBB allows influx 
of normally excluded molecules and inflammatory cells into the brain. Consequently, 
MMPs may be also increased and activated in the CNS of HIV-1 patients, leading to 
over-degradation of the ECM proteins that are important to cell structure and survival in 
the CNS (Cinque et al., 1998; Moore, 2011). To this end, we obtained 17 CSF samples 
including those from 8 HAND patients and 9 HD individuals (Table 2) and examined the 
protein levels and enzymatic activity of MMPs and TIMPs in these CSF samples. As 
shown in Fig. 5A, MMP-2, TIMP-1, and TIMP-2 were detected in all 17 CSF samples, 
albeit at various concentrations. Compared to HD, HAND patients had a significantly 
higher CSF level of TIMP-1 (Fig. 5A). There was a trend that CSF MMP-2 and TIMP-2 
levels were also elevated in HAND than in HD, but not significant (Fig. 5A). Strikingly, 
MMP-9 was detected by ELISA in all 8 HAND CSF samples, but was detected at a very 
low level in only 1 of the 9 CSF HD samples (Fig. 5A).  
The gelatin zymography assay revealed an MMP-2 band in every CSF sample (Fig. 
  
5B). The MMP-2 bands were much stronger in HAND patients than in HD individuals 
(Fig. 5B). Pooled data showed that the proteolytic activity of MMP-2 was significantly 
increased in the HAND CSF than that of HD CSF. The active form of MMP-9 was 
detected in all 8 HAND CSF samples, while none of the HD CSF samples showed the 
active MMP-9 enzyme bands (Fig. 5B). 
 
Imbalances between MMPs and TIMPs were linked to monocyte/macrophage 
activation in the peripheral blood, but not CSF, of HAND patients 
Over-activation of monocytes/macrophages profoundly contributes to systemic 
inflammation and BBB damage in HIV-1 patients, leading to HIV-1-associated 
neuropathogenesis (Anzinger et al., 2014; Gras and Kaul, 2010; Kim et al., 2005). The 
levels of sCD14 and sCD163 have been used as reliable markers of 
monocytes/macrophage activation and systemic inflammation in HIV-1 patients 
(Brenchley et al., 2006; Burdo et al., 2011a; Burdo et al., 2011b). We quantified plasma 
and CSF levels of sCD14 and sCD163 in HD, HAND, and/or NN groups. In agreement 
with previous reports (Burdo et al., 2011b; Lawn et al., 2000; Sandler et al., 2011), 
plasma levels of sCD14 and sCD163 were elevated in both NN and HAND patients 
when compared with HD individuals (Fig. 6A). There was no significant difference 
between NN and HAND in their plasma levels of sCD14 and sCD163 (Fig. 6A). Since 
sCD14 and sCD163 are likely shed by MMP proteolytic cleavage at the surface of 
monocytes/macrophages, we analyzed the correlations of increased plasma levels of 
sCD14 and sCD163 with plasma levels of MMPs and TIMPs. Spearman correlation 
analysis demonstrated that plasma levels of MMP-2 and TIMP-2 strongly correlated with 
  
the increased plasma levels of both sCD14 (r = 0.46, p = 0.01 and r = 0.55, p = 0.002, 
Fig. 6B) and sCD163 (r = 0.58, p = 0.001 and r = 0.68, p < 0.0001, Fig. 6C). There were 
no significant correlations between either sCD14 or sCD163 and plasma concentrations 
of MMP-9 (data not shown). Both sCD14 and sCD16 were detected in all CSF samples 
from HD and HAND individuals. However, neither sCD14 nor sCD163 was increased in 
the CSF of HAND patients when compared with HD individuals (Fig. S1). 
 
Inflammatory cytokines/chemokines affected the production and activation of 
MMPs in the CNS 
To clarify whether inflammatory factors are involved in regulation of production and 
activation of MMPs in the CNS, we simultaneously quantified CSF levels of 38 
cytokines/chemokines. As shown in Table 3, HAND patients had significantly higher 
CSF levels of 6 cytokines/chemokines including IFN-α2, TNF-α, Fractalkine, IL-1α, 
TGF-α, and MCP-1 when compared with HD individuals. Interestingly, the upregulated 
level of CSF MCP-1 was strongly correlated with the CSF level of MMP-2 in HAND 
patients (Fig. S2), suggesting that there is a complex interplay among the three types of 
factors (inflammatory cells, cytokines/chemokines, and MMPs) in the CNS of HIV-1 
patients. It is important to note that these HIV-1-negative donors had varied CNS 
symptoms, thereby their CSF samples are not representative of healthy individuals. 
To further explore the mechanisms underlying the induction and activation of 
MMPs in the CNS of HAND patients, we conducted proteomic analysis on the CSF 
samples. The Venn diagram in Fig. S3A illustrates the overview of the CSF proteome. 
Among these proteins, 57, 153, and 243 proteins were identified in the CSF of HD only, 
  
both HD and HAND, and HAND only, respectively. The 57 unique proteins found in the 
HD group were mainly defense/immunity proteins, enzyme modulators, extracellular 
matrix proteins, receptors, and signaling molecules (Fig. S3B). Defense/immunity 
proteins and signaling molecules that maintain brain homeostasis were the most 
abundant proteins (23.5%) (Fig. S3B). There were 243 proteins found only in the HAND 
CSF samples, and these proteins were mainly involved in calcium binding, cell 
adhension, membrane traffic, nucleic acid binding and redox process (Fig. S3C). 
Furthermore, the most abundant proteins were hydrolases (19%) and oxidoreductases 
(14.3%), indicating that enzymatic proteins and oxidative reactions were upregulated in 
HAND patients. Both HD and HAND samples had 153 proteins in common and divided 
into 12 groups based on their functional annotation (Fig. S3D). Among these shared 
proteins, 24 proteins were statistically different in their levels between HD and HAND 
samples (Fig. 7). Six and 18 proteins of these 24 proteins were downregulated and up-
regulated, respectively, in the CSF of HAND patients when compared with HD 
individuals. The down-regulated proteins included apolipoprotein A-II, calsyntenin-1, 
vitamin D-binding protein, complement factor B, C-type lectin domain family 3, and 
hemopexin, which are mainly associated with the calcium homeostasis and 
neuroimmunological function in the brain. The up-regulated proteins included 5 
epididymis secretory proteins that can be activated by IL-1β or TGF-β, indicating that 
inflammation occurs in the CNS of HAND patients. 
 
Discussion 
  
The principal finding of the present work is that imbalances between MMPs and 
TIMPs with distinct patterns occurred in both the peripheral blood and CNS of HIV-1 
patients, especially those with HAND. In the peripheral blood, the protein levels of 
MMP-2, MMP-9, TIMP-1, TIMP-2, and the enzymatic activity of MMP-2 and MMP-9 
were increased in HIV-1 patients with or without HAND when compared with HD 
individuals (Figs. 1, 2). The enzymatic activity of MMP-2, but not MMP-9, was further 
increased in HAND than in NN (Fig. 2). Importantly, the ratio of MMP-2/TIMP-2 was 
significantly increased in HAND patients, not in NN patients (Fig. 1C), which may 
represent a key risk indicator for HAND. In the CSF, induction and activation of MMP-9 
in HAND patients became particularly prominent as MMP-9 expression and enzymatic 
activity was detected in all 8 CSF samples from HAND patients, but only 1 of 9 CSF 
samples at a low level from HD individuals (Fig. 5). These results indicate that MMP-9 is 
not constitutively expressed in the CNS, but is likely induced de novo and activated in 
the CNS of HAND patients. In addition to MMP-9, MMP-2 enzymatic activity and TIMP-1 
expression, but neither expression of MMP-2 and TIMP-2 nor the ratio of MMP-2/TIMP-
2, were increased in the CSF samples from HAND patients when compared with HD 
individuals (Fig. 5). Taken together, the increased ratio of MMP-2/TIMP-2 in the 
peripheral blood may play a key role in HIV-1-associated neuropathogenesis by 
disrupting the BBB to increase the penetration of infected cells and neurotoxic 
substances from the blood into the CNS (Lakhan et al., 2013; Louboutin et al., 2010; 
Louboutin et al., 2011; Louboutin and Strayer, 2012; Power et al., 1993; Rosenberg et 
al., 1998; Singh, 2014; Spindler and Hsu, 2012; Strazza et al., 2011; Webster and 
Crowe, 2006). Additionally, the robust induction of MMP-9 and activation of MMP-2 and 
  
MMP-9 in the CNS of HIV-1 patients may not only damage the BBB, but also degrade 
nerve tissue proteins to induce death of neurons (Webster and Crowe, 2006). Thus, the 
imbalances of MMPs and TIMPs occurring in the peripheral blood and CNS of HIV-1 
patients likely play a crucial role in the HIV-1-associated neuropathogenesis by 
disrupting the BBB, increasing influx of inflammatory cells, and degrading neuronal 
survival molecules. 
MMPs and TIMPs are expressed by various cell types, and their gene expressions 
are regulated by a variety of extracellular factors including cytokines, growth factors, 
and cell-cell interactions (Lambert et al., 2004; Westermarck and Kahari, 1999). Studies 
have demonstrated that activated monocytes/macrophages orchestrate these events 
and play a central role in BBB injury in HIV-1 patients (Anzinger et al., 2014; Gras and 
Kaul, 2010; Kim et al., 2005). Activated monocytes/macrophages increase the 
production of MMPs and inflammatory cytokines, enhance infiltration of inflammatory 
cells and HIV-1-infected cells into the CNS, and accelerate the influx of neurotoxic 
substances into the brain, thereby promoting HIV-1-associated neuropathogenesis 
(Anzinger et al., 2014; Gras and Kaul, 2010; Kim et al., 2005). Along these lines, we 
measured circulating levels of sCD14 and sCD163, two markers of 
monocyte/macrophage activation and inflammation (Brenchley et al., 2006; Burdo et al., 
2011a; Burdo et al., 2011b), in the plasma from HIV-1 patients and HD individuals. In 
agreement with previous reports (Burdo et al., 2011b; Lawn et al., 2000; Sandler et al., 
2011), sCD14 and sCD163 were elevated in the plasma of HAND and NN patients 
when compared with HD individuals (Fig. 6). Interestingly, upregulation of plasma MMP-
2 in HIV-1 patients strongly correlated with the increased levels of both sCD14 and 
  
sCD163 (Fig. 6), suggesting that sCD14 and sCD163 are likely shed via proteolytic 
cleavage by MMPs, especially MMP-2, at the surface of monocytes/macrophages. This 
result provides insight into the molecular mechanisms underlying the increased 
production of sCD14 and sCD163 in the peripheral blood of HIV-1 patients. In addition, 
upregulation of plasma MMP-2 positively correlated with viral loads and negatively 
correlated with CD4 counts in the HIV-1 patients included in this study (Fig. 3). We 
acknowledge that these results are primarily derived from patients not receiving 
virologically suppressive cART, and thus these data may not apply to HAND patients 
who have undetectable plasma viral loads. 
To clarify whether the imbalances between MMPs and TIMPs found in both the 
peripheral blood and CNS of HIV-1 patients, especially those with neurocognitive 
disorders, was driven by inflammatory factors, we examined the profiles of 38 
cytokines/chemokines in the plasma and CSF samples from HAND patients and HD 
individuals. HAND patients had significantly higher levels of MCP-1 and TNF-α in both 
the peripheral blood (data not shown) and CSF (Table 3, Fig. S2A). MCP-1 is one of the 
key chemokines that regulate migration and infiltration of monocytes/macrophages 
(Deshmane et al., 2009). We found that the upregulated CSF levels of MCP-1 and 
MMP-2 strongly correlated in HAND patients (Fig. S2B), suggesting that MMPs and 
MCP-1 may be two key players in the pathogenesis of HAND. It likely occurs that MMPs 
damage the BBB, allowing increased penetration of activated/infected 
monocytes/macrophages into the CNS. These migrated monocytes/macrophages 
directly or indirectly produce MCP-1 and other cytokines/chemokines to attract more 
activated cells into the CNS, leading to accelerated production of MMPs. Thus, MMPs 
  
and MCP-1 generate a positive feedback loop to enhance their neuropathic effects in 
HIV-1 patients. It is important to note that the CSF samples were obtained from HD 
individuals who had varied CNS symptoms, thereby not representing that from truly 
healthy individuals.  
Since TNF-α was increased in both the peripheral blood (data not shown) and CSF 
(Table 3) in HIV-1 patients, we tested whether TNF-α affected production and activation 
of MMPs by brain cells including astrocytes and brain capillary microvascular 
endothelial cells. We found that a human astrocyte cell line (U87MG), but not the 
human brain capillary microvascular endothelial cell line (hCMEC/D3), produced both 
the latent and active forms of MMP-2 in response to TNF-α stimulation in a time-
dependent manner (Fig. S4). However, neither U87MG nor hCMEC/D3 cells produced 
any forms of MMP-9 (Fig. S4). Therefore, there are still questions remaining about the 
induction and activation of MMP-9 in the CNS of HIV-1 patients: (1) which types of 
neural cells can be induced to produce MMP-9, (2) what factors trigger the production 
and activation of MMP-9, and (3) the molecular mechanisms underlying the robust 
induction and activation of MMP-9 found in the CNS of HAND patients.  
Overwhelming evidence has demonstrated that HIV-1 invades the CNS in part by 
breaking down the BBB and BBB breakdown, which represents a key step in HIV-1-
associated neuropathy. However, there is no evidence thus far showing that plasma 
from HIV-1 patients can directly impair the BBB integrity and function. Utilizing the 
human astrocyte cell line U87MG and brain capillary microvascular endothelial cell line 
hCMEC/D3 to establish an in vitro BBB model as previously described (Eugenin and 
Berman, 2003; Eugenin et al., 2011), we demonstrated that plasma from HIV-1 patients 
  
was able to directly impair the permeability of the BBB model as FITC-dextran diffusion 
and transmigration of monocytes/macrophages across the BBB was significant (Fig. 4). 
Importantly, pre-treatment of the BBB with GM6001, a pan-MMP inhibitor (Afonso et al., 
2013), ameliorated the impairment of the BBB permeability (data not shown), indicating 
that MMPs in the plasma from HIV-1 patients mediated the impairment of the BBB 
permeability. To our knowledge, this is the first evidence of plasma from HIV-1 patients 
directly impairing the BBB permeability and function, and the impairment is at least 
partially mediated by MMPs/TIMPs imbalances in the plasma.  
In summary, imbalances between MMPs and TIMPs with distinct patterns occur in 
both the blood and CNS of HIV-1 patients, especially those with neurocognitive 
disorders. Robust expression and activation of MMPs not only damage the BBB and 
CNS tissues, but also contribute to inflammation of the CNS, thereby playing a key role 
in the pathogenesis of HAND. Inhibition of MMP activity may represent a therapeutic 
strategy to mitigate MMP-related damage during HIV-1 infection. However, it should be 
noted that the sample size of the individual groups was too small to allow a detailed 
analysis of each subtype of HAND. Additionally, the CSF samples were obtained from 
HD individuals who had varied CNS symptoms and thereby may not represent those 
from healthy individuals. Therefore, the simian immunodeficiency virus (SIV)/macaque 
animal model of HIV-1 infection may be used to address these issues and to further 
study the role of dysregulated MMPs/TIMPs in the pathogenesis of neuroAIDS. 
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Figure legend 
Fig. 1. Imbalances between MMPs and TIMPs occurred in the peripheral blood of 
HAND patients. Plasma samples from 9 HD, 9 NN, and 19 HAND individuals were 
subjected to ELISAs to determine the levels of MMP-2, MMP-9, TIMP-1, and TIMP-2. A) 
and B) The scatter plots show the distribution of plasma levels (ng/mL) of MMP-2, 
MMP-9, TIMP-1, and TIMP-2 . C) The ratio of MMP-2/TIMP-2 and MMP-9/TIMP-1 in the 
plasma samples. Each dot in the plots represents data from a single individual. Lines 
represent mean ± SEM. HD, HIV-1-negative individuals; NN, HIV-1 patients who had no 
neurocognitive disorders; HAND, HIV-1-associated neurocognitive disorders; ns, not 
significant; * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
Fig. 2. Enzymatic activity of MMP-2 and MMP-9 was increased in the peripheral 
blood of HIV-1 patients. Enzymatic activity of MMP-2 and MMP-9 in the plasma 
samples from HD, NN, and HAND individuals was evaluated using the gelatin 
zymography assay. A) Representative zymography results of the plasma samples from 
3 HD, 2 NN, and 4 HAND individuals. B) Enzymatic activity of MMP-2 and MMP-9 in the 
plasma samples from HD, NN, and HAND individuals was quantified using Image J 
software. Each dot in the plots represents data from a single individual. Lines represent 
mean ± SEM. A.U., arbitrary unit; HD, HIV-1-negative individuals; NN, HIV-1 patients 
who had no neurocognitive disorders; HAND, HIV-1-associated neurocognitive 
disorders; ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001. 
 
  
Fig. 3. Correlations between plasma MMPs or TIMPs levels and markers of viral 
pathogenesis in HIV-1 patients. Correlation between plasma level of MMP-2 or TIMP-
2 and viral load (A and C) or CD4 count (B and D) in HAND patients. Each dot in the 
plots represents data from a single individual. Significance was determined using the 
Spearman correlation test. Spearman correlation coefficient and p value (r and p) are 
indicated. 
 
Fig. 4. Effects of plasma from HIV-1 patients on BBB permeability and PBMCs 
transmigration. Fresh PBMCs from healthy donors were added into inserts of in vitro 
BBB model that were untreated or treated with plasma from HD, HIV-1 patients, or 
MCP-1. A) The permeability of the BBB model was analyzed after treatment with 
plasma from HD or HIV-1 patients for 24 h by quantifying the passage of FITC-
conjugated Dextran through co-cultures. B) and C) Transmigrated cells in the lower 
chamber were collected and stained for flow cytometric analysis to quantify the number 
of monocytes (CD45+CD14+) in the transmigrated population of cells. Forward and side 
scatter were used to determine transmigrated cell gating. Data from at least 3 donors 
were expressed as mean ± SEM. * p < 0.05; *** p < 0.001. 
 
Fig. 5. Expression and activation of MMPs and TIMPs in the CSF from HIV-1-
negative individuals and HAND patients. CSF samples collected from 9 HD and 8 
HAND patients were studied. A) The scatter plots showed CSF levels of MMP-2, MMP-
9, TIMP-1, and TIMP-2 (ng/mL). B) Enzymatic activity of MMP-2 and MMP-9 from 4 HD 
and 4 HAND, and quantification data of MMP-2 and MMP-9 in all CSF samples tested. 
  
A.U., arbitrary unit; HD, HIV-1-negative individuals; HAND, HIV-1-associated 
neurocognitive disorders; ns, not significant; ** p < 0.05; *** p < 0.001. 
 
Fig. 6. Correlations between MMPs and monocyte/macrophage activation markers 
in the peripheral blood of HIV-1 patients. A) Plasma samples from 9 HD, 9 NN, and 
19 HAND individuals were subjected to ELISAs to determine the levels of sCD14 and 
sCD163 (ng/mL). Each dot in the plots represents data from a single individual. Lines 
represent mean ± SEM. B) and C) Correlation between plasma sCD14 or sCD163 and 
MMP-2 or TIMP-2. Significance was determined using the Spearman correlation test. 
Spearman correlation coefficient and p value (r and p) are indicated.  
 
Fig. 7. Proteomics analysis of CSF samples from HIV-1-negative donors and 
HAND patients. Protein profile analysis, as shown in the heat map, reveals the proteins 
differentially expressed between HIV-1-negative and HAND CSF samples.  
 
Fig. S1. Activation intensity of monocytes/macrophages in HAND CSF samples. 
CSF samples were subjected to ELISAs to determine the levels of sCD14 and sCD163 
(ng/mL). Each dot in the plots represents data from a single individual. Lines represent 
mean ± SEM. HD, HIV-1-negative individuals; HAND, HIV-1-associated neurocognitive 
disorders; ns, not significant. 
 
Fig. S2. Correlations between MMPs and monocyte/macrophage activation 
markers in the CSF samples of HIV-1 patients. A) CSF level of MCP-1 was 
  
determined using the multiplex immunoassay. Data were presented as mean ± SEM. B) 
Correlations between CSF levels of MMP-2 and MCP-1 in HAND patients were 
demonstrated. Significance was determined using the Spearman correlation test. 
Spearman correlation coefficients (r and p values) were indicated. 
 
Fig. S3. Proteomic analysis of CSF samples from HAND patients. A) The Venn 
diagram illustrates an overview of the CSF proteome. B-D) Characteristics of CSF 
protein profiles in HD only, HAND only, and both HD and HAND, respectively. Proteins 
were grouped based on their biological functions. 
 
Fig. S4. Effects of inflammatory cytokines/chemokines on the production and 
activation of MMPs in the CNS. To test whether neural cells produced latent and 
active forms of MMP-2 and MMP-9, astrocytes (U87MG) (2×105) and hCMEC/D3 cells 
(2×105) were cultured overnight, followed by treatment with 20 ng/mL TNF-α (Biolegend, 
San Diego, CA) in serum-free medium. After incubation for up to 72 h, cell-free 
supernatants were collected for analysis of MMP-2 and MMP-9 expression and 
activation. A) Enzymatic activity of MMPs in the supernatants of TNF-α-treated 
astrocytes (U87MG) and brain capillary microvascular endothelial cells (hCMEC/D3). B) 
Pooled data showed the comparison of enzymatic activity of MMP-2 in the supernatant 
from astrocytes (U87MG) treated with TNF-α (20 ng/mL) versus medium. TNF-α 
stimulation was performed at least 3 times. *, p<0.05; **, p<0.01; ***, p<0.001. 
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Table 1. Demographics and clinical characteristics of study subjects 
Characteristics HAND (n=19) NN (n=9) p value HD (n=9) 
Age (years) 45 ± 2 48 ± 2 0.4 47 ± 5 
Gender (% Male) 78 90 0.4 67 
Race (% White) 67 63 0.9 56 
CD4 count (cells/µL) 150 ± 34 301 ± 91 0.1 ND 
Plasma HIV RNA (log10/mL) 4.0 ± 0.3 3.4 ± 0.5 0.3 ND 
Note: HAND, HIV-1-associated neurocognitive disorders; NN, HIV-1 patients who had 
no neurocognitive disorders; HD, HIV-1-negative donors; ND, not determined.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2. Characteristics of HAND and HIV-1-negative individuals, CSF 
CSF ID Gender (M/F) 
Age 
(year) Race
NeuroAIDS 
status 
CSF viral load       
(log10/mL) cART 
HAND 
  
 
   
NNTC005 F 38 NW ANI 4.9 missing 
NNTC026 M 44 W ANI missing ABC+APV+EFV 
NNTC012 M 42 NW ANI 3.9 missing 
NNTC037 M 54 W ANI 4.9 ART- 
NNTC010 M 62 W MND missing 3TC+KTA+RTV+TFV
NNTC068 M 60 W MND missing missing 
NNTC058 M 47 W HAD 1.7 3TC+ABC+APV 
NNTC126 M 61 W HAD 1.7 ATV+EPZ+RTV 
HIV-1-negative 
 
 
   
T44 M 54  
   
T45 F 57  
   
T51 F 69  
   
T52 F 24  
   
T53 F 74  
   
T54 F 76  
   
T55 F 24  
   
T56 M 91  
   
T57 F 46        
  
Note: M, male; F, female; W, white; NW, non-white; ANI, asymptomatic neurocognitive 
impairment; MND, mild neurocognitive disorder; HAD, HIV-1-associated dementia; ABC, 
abacavir; APV, amprenavir; EFV, efavirenz; 3TC, lamivudine; KTA, lopinavir/ritonavir; 
RTV, ritonavir; TFV, tenofivir; ATV, atazanavir; EPZ, ABC + lamivudine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 3. Comparison of CSF levels of 38 cytokines/chemokines between HD and 
HAND patients 
Cytokine/chemokine Groups (Mean ± SEM) (pg/mL) p value 
HD (n=9) HAND (n=8) 
IFN-α2 16.7 ± 4.2 38.9 ± 3.6 0.0045 
TNF-α 1.1 ± 0.2 3.0 ± 0.6 0.0050 
MCP-1 1994.0 ± 184.3 3577.0 ± 571.6 0.0207 
IL-1α 33.8 ± 12.6 164.1 ± 69.6 0.0267 
Fractalkine 69.6 ± 11.6 103.6 ± 14.4 0.0383 
TGF-α 2.4 ± 0.3 13.7 ± 7.0 0.0484 
CCL5 43.2 ± 0.4 59.6 ± 13.0 0.0660 
IP-10 950.2 ± 247.7 3627.0 ± 1581.0 0.0712 
Flt-3L 42.2 ± 13.3 208.0 ± 113.5 0.1206 
GM-CSF 8.8 ± 1.4 12.8 ± 2.2 0.1857 
IL-17α 1.5 ± 0.6 0.4 ± 0.2 0.3448 
IL-8 42.7 ± 8.8 72.9 ± 22.7 0.3704 
IL-3 8.6 ± 1.6 7.0 ± 0.9 0.4234 
IL-6 75.1 ± 60.0 15.0 ± 7.7 0.5946 
G-CSF 151.6 ± 83.1 64.9 ± 23.3 0.6371 
  
IL-15 4.4 ± 1.0 4.4 ± 1.1 0.6372 
IL-9 3.2 ± 0.7 4.1 ± 1.0 0.6646 
TNF-β 0/9 1/8 
VEGF 0/9 5/8 
IL-12p70 0/9 1/8 
IFN-γ 6/9 4/8 
GRO 2/9 5/8 
IL-10 0/9 2/8 
MCP-3 2/9 1/8 
IL-12p40 1/9 1/8 
MDC 2/9 5/8 
IL-13 1/9 1/8 
EGF 0/9 3/8 
FGF-2 0/9 4/8 
Eotaxin 1/9 5/8 
sCD40L 5/9 4/8 
MIP-1α 1/9 1/8 
MIP-1β 6/9 2/8 
IL-7 1/9 4/8 
IL-4 0/9 1/8 
IL-5 0/9 2/8 
IL-RA 5/9 5/8 
  
IL-1β 0/9 1/8 
IL-2 6/9 2/8   
Note: HD, HIV-1-negative donors; HAND, HIV-1-associated neurocognitive disorders; 
x/9 or x/8, number of CSF samples had detectable levels of cytokines/chemokines as 
indicated out of the total of 9 or 8 CSF samples.  
  
  
Highlights 
 MMPs/TIMPs imbalance with distinct patterns occurred in both the peripheral blood 
and CNS of HAND patients. 
 MMP-2/TIMP-2 upregulation was associated with viral pathogenesis and 
monocyte/macrophage activation in the peripheral blood. 
 Chronic inflammation, but not the M/MΦ activation, may be linked to the 
MMPs/TIMPs dysregulation in the CNS of HAND patients. 
 Plasma from HIV-1 patients can directly damage the in vitro BBB integrity. 
 
 
